Vistagen Therapeutics, Inc. VTGN
0.17 USD -0.01 (-5.82%)
As ofNov 16, 2026, 9:33 AM EST
0.168 Day range 0.1799
0.16 52-week range 5.14
- YTD
- -74.24%
- 1 year
- -95.53%
News
benzinga.com VistaGen Therapeutics Q2 EPS $(0.24) Beats $(0.38) Estimate, Sales $138.000K Miss $250.000K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.38) by 35.14 percent. This is a 55.56 percent increase over losses…
globenewswire.com Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility…
defenseworld.net VistaGen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Thursday VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) is projected to release its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of…benzinga.com Vistagen Intends To Adopt Incorporate Interim Assessments Of Fasedienol's Effect Through eDiaries, Qualitative Patient Surveys In Phase 3 Trial Design After Type C Meeting With FDA Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced a regulatory update from its recent, productive…
globenewswire.com Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder Constructive feedback from FDA clarifies potential Phase 3 development path forward Constructive feedback from FDA clarifies potential Phase 3 development path forwardbenzinga.com Vistagen Therapeutics Implements 31% Workforce Reduction On October 26, 2026; Workforce Reduction Expected To Save $3.20M In Salary And Benefits Annually On October 26, 2026, Vistagen Therapeutics, Inc. (the "Company") implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate
